Nautilus Q4 operating expenses fall 23%, net loss narrows

Overview

• Proteome analysis platform's Q4 operating expenses decreased 23% yr/yr

• Net loss for Q4 narrowed compared to the previous year

• Company does not anticipate material revenue from Early Access Program in 2026

Outlook

• Company expects operating expenses to rise 15-20% in 2026

• Nautilus anticipates no material revenue from Early Access Program in 2026

• Company believes cash reserves will fund operations through 2027

Result Drivers

• TAU PROTEOFORMS - Progress in processing and analyzing Tau proteoform samples supported platform validation and scientific publications

• COST MANAGEMENT - Decrease in operating expenses attributed to reduced salaries, benefits, and development costs

• EARLY ACCESS PROGRAM - Launched Iterative Mapping Early Access Program with encouraging initial customer response

Company press release: ID:nGNX2lMQfg

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $2.50, about 13.5% below its February 25 closing price of $2.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.